secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0001628280-25-022864
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

C4 Therapeutics Q1 net loss $26.3M; cemsidomide 50% ORR at 100 µg in MM
-----------------------------------------------------------------------

- Revenue $7.2M (up from $3.0M YoY); net loss $0.37/share vs $0.41.
- Cemsidomide Phase 1 MM dose escalation complete; 100 µg QD safe for expansion; ORR 50% at 100 µg, 40% at 75 µg.
- One patient achieved MRD-negative complete response after prior T-cell engager therapies.
- Will not advance CFT1946 beyond Phase 1; seeking partnership for BRAF program.
- Cash $234.7M, runway into 2027; earned $4M from two Roche preclinical milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828025022864/0001628280-25-022864-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828025022864/cccc-20250507.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-022864

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer